PTSD
MCID: PST028
MIFTS: 59

Post-Traumatic Stress Disorder (PTSD)

Categories: Mental diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Post-Traumatic Stress Disorder

MalaCards integrated aliases for Post-Traumatic Stress Disorder:

Name: Post-Traumatic Stress Disorder 11 28 41 14 16 71 75 31
Post Traumatic Stress Disorder 75 33
Traumatic Neurosis 11 33
Ptsd 11 47
Ptsd - [post Traumatic Stress Disorder] 33
Stress Disorders, Post-Traumatic 43
Posttraumatic Stress Disorder 14
Trauma-Related Disorders 33

Classifications:



External Ids:

Disease Ontology 11 DOID:2055
ICD9CM 34 309.81
MeSH 43 D013313
NCIt 49 C3389
SNOMED-CT 68 192415000
ICD10 31 F43.1
ICD11 33 2070699808
UMLS 71 C0038436

Summaries for Post-Traumatic Stress Disorder

MedlinePlus: 41 What is post-traumatic stress disorder (PTSD)? Post-traumatic stress disorder (PTSD) is a mental health disorder that some people develop after they experience or see a traumatic event. The traumatic event may be life-threatening, such as combat, a natural disaster, a car accident, or sexual assault. But sometimes the event is not necessarily a dangerous one. For example, the sudden, unexpected death of a loved one can also cause PTSD. It's normal to feel afraid during and after a traumatic situation. The fear triggers a "fight-or-flight" response. This is your body's way of helping to protect itself from possible harm. It causes changes in your body such as the release of certain hormones and increases in alertness, blood pressure, heart rate, and breathing. In time, most people recover from this naturally. But people with PTSD don't feel better. They feel stressed and frightened long after the trauma is over. In some cases, the PTSD symptoms may start later on. They might also come and go over time. What causes post-traumatic stress disorder (PTSD)? Researchers don't know why some people get PTSD and others don't. Genetics, neurobiology, risk factors, and personal factors may affect whether you get PTSD after a traumatic event. Who is at risk for post-traumatic stress disorder (PTSD)? You can develop PTSD at any age. Many risk factors play a part in whether you will develop PTSD. They include: Your sex; women are more likely to develop PTSD Having had trauma in childhood Feeling horror, helplessness, or extreme fear Going through a traumatic event that lasts a long time Having little or no social support after the event Dealing with extra stress after the event, such as loss of a loved one, pain and injury, or loss of a job or home Having a history of mental illness or substance use What are the symptoms of post-traumatic stress disorder (PTSD)? There are four types of PTSD symptoms, but they may not be the same for everyone. Each person experiences symptoms in their own way. The types are: Re-experiencing symptoms, where something reminds you of the trauma and you feel that fear again. Examples include Flashbacks, which cause you to feel like you are going through the event again Nightmares Frightening thoughts Avoidance symptoms, where you try to avoid situations or people that trigger memories of the traumatic event. This may cause you to Stay away from places, events, or objects that are reminders of the traumatic experience. For example, if you were in a car accident, you might stop driving. Avoiding thoughts or feelings related to the traumatic event. For example, you might try to stay very busy to try to avoid thinking about what happened. Arousal and reactivity symptoms, which may cause you to be jittery or be on the lookout for danger. They include Being easily startled Feeling tense or "on edge" Having difficulty sleeping Having angry outbursts Cognition and mood symptoms, which are negative changes in beliefs and feelings. They include Trouble remembering important things about the traumatic event Negative thoughts about yourself or the world Feeling blame and guilt No longer being interested in things you enjoyed Trouble concentrating The symptoms usually start soon after the traumatic event. But sometimes they may not appear until months or years later. They also may come and go over many years. If your symptoms last longer than four weeks, cause you great distress, or interfere with your work or home life, you might have PTSD. How is post-traumatic stress disorder (PTSD) diagnosed? A health care provider who has experience helping people with mental illnesses can diagnose PTSD. The provider will do a mental health screening and may also do a physical exam. To get a diagnosis of PTSD, you must have all of these symptoms for at least one month: At least one re-experiencing symptom At least one avoidance symptom At least two arousal and reactivity symptoms At least two cognition and mood symptoms What are the treatments for post-traumatic stress disorder (PTSD)? The main treatments for PTSD are talk therapy, medicines, or both. PTSD affects people differently, so a treatment that works for one person may not work for another. If you have PTSD, you need to work with a mental health professional to find the best treatment for your symptoms.: Talk therapy, or psychotherapy, which can teach you about your symptoms. You will learn how to identify what triggers them and how to manage them. There are different types of talk therapy for PTSD. Medicines can help with the symptoms of PTSD. Antidepressants may help control symptoms such as sadness, worry, anger, and feeling numb inside. Other medicines can help with sleep problems and nightmares. Can post-traumatic stress disorder (PTSD) be prevented? There are certain factors that can help reduce the risk of developing PTSD. These are known as resilience factors, and they include: Seeking out support from other people, such as friends, family, or a support group Learning to feel good about your actions in the face of danger Having a coping strategy or a way of getting through the bad event and learning from it Being able to act and respond effectively despite feeling fear Researchers are studying the importance of the resilience and risk factors for PTSD. They are also studying how genetics and neurobiology can affect the risk of PTSD. With more research, someday it may be possible to predict who is likely to develop PTSD. This could also help in finding ways to prevent it. NIH: National Institute of Mental Health

MalaCards based summary: Post-Traumatic Stress Disorder, also known as post traumatic stress disorder, is related to acute stress disorder and chronic pain, and has symptoms including nervousness An important gene associated with Post-Traumatic Stress Disorder is LINC01090 (Long Intergenic Non-Protein Coding RNA 1090), and among its related pathways/superpathways are Signal Transduction and GPCR downstream signalling. The drugs Diazepam and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, prefrontal cortex and amygdala, and related phenotypes are Reduced mammosphere formation and nervous system

Disease Ontology: 11 An anxiety disorder which results from a traumatic experience that results in psychological trauma.

Wikipedia: 75 Post-traumatic stress disorder (PTSD)[a] is a mental and behavioral disorder that can develop because of... more...

Related Diseases for Post-Traumatic Stress Disorder

Diseases related to Post-Traumatic Stress Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 743)
# Related Disease Score Top Affiliating Genes
1 acute stress disorder 33.2 SLC6A4 POMC OGN NR3C1 HTR2A CRHR1
2 chronic pain 31.8 CNR1 BDNF
3 apnea, obstructive sleep 31.5 POMC NR3C2 HTR2A BDNF
4 anxiety 31.5 SLC6A4 SLC6A3 POMC NR3C1 NPY MAOA
5 amnestic disorder 31.5 PREP OGN HTR1A FOS BDNF
6 sleep apnea 31.5 SLC6A4 NPY HTR2A BDNF
7 adult syndrome 31.5 POMC NR3C1 H2AC18 CRH
8 personality disorder 31.4 SLC6A4 SLC6A3 NR3C1 MAOA HTR2A HTR1A
9 alcohol use disorder 31.4 SLC6A4 SLC6A3 POMC OGN NPY MAOA
10 alexithymia 31.3 SLC6A4 HTR2A H2AC18 DRD2 CRH BDNF
11 somatization disorder 31.3 SLC6A4 POMC CRH
12 major depressive disorder 31.3 SLC6A4 SLC6A3 POMC NR3C2 NR3C1 NPY
13 headache 31.2 SLC6A4 NPY HTR2A BDNF
14 neurotic disorder 31.2 SLC6A4 POMC MAOA HTR2A HTR1A CRH
15 dissociative disorder 31.2 SLC6A4 OGN HTR2A BDNF
16 borderline personality disorder 31.2 SLC6A4 SLC6A3 NR3C1 MAOA HTR2A HTR1A
17 generalized anxiety disorder 31.2 SLC6A4 POMC MAOA HTR2A HTR1A H2AC18
18 panic disorder 31.2 SLC6A4 SLC6A3 POMC NPY MAOA HTR2A
19 dissociative amnesia 31.2 OGN CRH BDNF
20 psychotic disorder 31.2 SLC6A4 SLC6A3 NPY MAOA HTR2A HTR1A
21 adjustment disorder 31.1 SLC6A4 POMC OGN HTR2A HTR1A CRH
22 dementia 31.1 SLC6A3 MAOA HTR2A HTR1A DRD2 BDNF
23 brunner syndrome 31.1 SLC6A4 MAOA HTR2A
24 postpartum depression 31.1 SLC6A4 POMC NR3C1 MAOA HTR2A HTR1A
25 sleep disorder 31.1 SLC6A4 SLC6A3 POMC NPY HTR2A HTR1A
26 fibromyalgia 31.1 SLC6A4 PREP POMC NPY MAOA HTR2A
27 agoraphobia 31.0 SLC6A4 MAOA HTR2A HTR1A CRH BDNF
28 polysubstance abuse 31.0 DRD2 CNR1
29 obsessive-compulsive disorder 31.0 SLC6A4 SLC6A3 POMC NPY MAOA HTR2A
30 cocaine dependence 31.0 SLC6A4 SLC6A3 POMC DRD2 CRH
31 autism spectrum disorder 31.0 SLC6A4 SLC6A3 NR3C2 NR3C1 MAOA HTR1A
32 conduct disorder 31.0 SLC6A4 SLC6A3 POMC MAOA DRD2
33 bulimia nervosa 31.0 SLC6A4 SLC6A3 NPY MAOA HTR2A DRD2
34 antisocial personality disorder 31.0 SLC6A4 SLC6A3 MAOA HTR2A DRD2
35 bipolar disorder 31.0 SLC6A4 SLC6A3 PREP NR3C1 MAOA HTR2A
36 disease of mental health 30.9 SLC6A4 SLC6A3 POMC NPY MAOA HTR2A
37 autism 30.9 SLC6A4 SLC6A3 NR3C2 NR3C1 MAOA HTR2A
38 irritable bowel syndrome 30.9 SLC6A4 POMC HTR2A HTR1A FOS CRHR1
39 leptin deficiency or dysfunction 30.9 POMC NPY CRH BDNF
40 alcohol dependence 30.9 SLC6A4 SLC6A3 POMC NPY MAOA HTR2A
41 toxic encephalopathy 30.8 SLC6A3 H2AC18 BDNF
42 dysthymic disorder 30.8 SLC6A4 SLC6A3 POMC MAOA HTR2A HTR1A
43 mood disorder 30.8 SLC6A4 SLC6A3 POMC NR3C2 NR3C1 NPY
44 substance abuse 30.8 SLC6A4 SLC6A3 POMC OGN NPY MAOA
45 pituitary adenoma 30.8 POMC NR3C1 DRD2 CRH
46 sexual health disorder 30.8 SLC6A4 MAOA HTR2A HTR1A H2AC18
47 chronic fatigue syndrome 30.8 SLC6A4 POMC NR3C1 MAOA HTR1A H2AC18
48 movement disease 30.8 SLC6A3 HTR2A HTR1A H2AC18 DRD2 BDNF
49 pain agnosia 30.8 POMC HTR1A FOS CRH CNR1 BDNF
50 epilepsy 30.8 SLC6A3 POMC NPY MAOA HTR1A CNR1

Comorbidity relations with Post-Traumatic Stress Disorder via Phenotypic Disease Network (PDN):


Anxiety Dysthymic Disorder
Major Depressive Disorder

Graphical network of the top 20 diseases related to Post-Traumatic Stress Disorder:



Diseases related to Post-Traumatic Stress Disorder

Symptoms & Phenotypes for Post-Traumatic Stress Disorder

UMLS symptoms related to Post-Traumatic Stress Disorder:


nervousness

GenomeRNAi Phenotypes related to Post-Traumatic Stress Disorder according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 BDNF CRHR1 DRD2 MAOA NR3C1 NR3C2

MGI Mouse Phenotypes related to Post-Traumatic Stress Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.28 BDNF CNR1 CRH CRHR1 DRD2 FOS
2 homeostasis/metabolism MP:0005376 10.22 BDNF CNR1 CRH CRHR1 DRD2 FOS
3 normal MP:0002873 10.16 BDNF CNR1 CRH CRHR1 DRD2 FOS
4 behavior/neurological MP:0005386 10.09 BDNF CNR1 CRH CRHR1 DRD2 FOS
5 no phenotypic analysis MP:0003012 10.03 BDNF CNR1 CRH CRHR1 DRD2 HTR1A
6 adipose tissue MP:0005375 9.97 CNR1 CRH DRD2 FOS NPY NR3C1
7 endocrine/exocrine gland MP:0005379 9.96 BDNF CRH CRHR1 DRD2 FOS HTR2A
8 integument MP:0010771 9.36 BCL2A1 BDNF CNR1 CRH DRD2 FOS
9 taste/olfaction MP:0005394 9.26 BDNF CNR1 DRD2 SLC6A3

Drugs & Therapeutics for Post-Traumatic Stress Disorder

Drugs for Post-Traumatic Stress Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 320)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
2
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
5
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
6
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
7
Ziprasidone Approved Phase 4 146939-27-7 60854
8
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
9
Histamine Approved, Investigational Phase 4 51-45-6 774
10
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
11
Atomoxetine Approved Phase 4 82248-59-7, 83015-26-3 54841
12
Mianserin Approved, Investigational Phase 4 24219-97-4 4184
13
Levodopa Approved Phase 4 59-92-7, 63-84-3 6047
14
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
15
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
16
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
17
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
18
Haloperidol Approved Phase 4 52-86-8 3559
19
Minocycline Approved, Investigational Phase 4 10118-90-8, 13614-98-7 54675783 5281021
20
Asenapine Approved Phase 4 85650-56-2, 65576-45-6 163091
21
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
22
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
23
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
24
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
25
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
26
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
27
Suvorexant Approved, Investigational Phase 4 1030377-33-3 57505028 24965990
28
Promethazine Approved, Investigational Phase 4 60-87-7 4927
29
Eltanolone Approved, Investigational Phase 4 516-54-1, 128-20-1 31402 92786
30
Pimavanserin Approved, Investigational Phase 4 706779-91-1 10071196
31
Sertraline Approved Phase 4 79617-96-2 68617
32
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
34
Prazosin Approved Phase 4 19216-56-9 4893
35
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
36
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
37
Duloxetine Approved Phase 4 136434-34-9, 116539-59-4 60835
38 Olive Phase 4
39 Antiemetics Phase 4
40 Gastrointestinal Agents Phase 4
41 Antineoplastic Agents, Hormonal Phase 4
42 Serotonin 5-HT1 Receptor Agonists Phase 4
43
Quetiapine Fumarate Phase 4 111974-72-2
44 Contraceptives, Postcoital Phase 4
45 Contraceptives, Oral Phase 4
46 Contraceptive Agents Phase 4
47
Histamine phosphate Phase 4 51-74-1 134614
48 Serotonin 5-HT3 Receptor Antagonists Phase 4
49 Dihydroxyphenylalanine Phase 4
50
Vilazodone Hydrochloride Phase 4 163521-08-2

Interventional clinical trials:

(show top 50) (show all 1923)
# Name Status NCT ID Phase Drugs
1 The Effect of 21-Days Intranasal Oxytocin on Clinical Symptoms and Social Function in Patients With Post Traumatic Stress Disorder (PTSD), a Randomized Controled Trail Unknown status NCT02336568 Phase 4 Oxytoine;PLACEBO
2 A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder Unknown status NCT01535586 Phase 4
3 Propranolol Reactivation Mismatch (PRM) Treatment for PTSD: A Pilot Study Unknown status NCT03652922 Phase 4 Reactivation Mismatch
4 Suvorexant and Trauma Related Insomnia Unknown status NCT02704754 Phase 4 suvorexant
5 Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure Unknown status NCT00633685 Phase 4 Fluoxetine;Placebo
6 A Prospective Double Blind Randomized Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder Unknown status NCT00134446 Phase 4
7 Double Blind, Placebo-Controlled Trial of THC as add-on Therapy for PTSD Unknown status NCT00965809 Phase 4 Tetrahydrocannabinol
8 Administration of Prazosin to Prevent PTSD After Sexual Assault Unknown status NCT03997864 Phase 4 Prazosin;Placebos
9 Early Pharmacological Intervention With Diazepam in the Emergency Room Setting to Prevent Posttraumatic Stress Disorder (PTSD). Unknown status NCT01221883 Phase 4 Diazepam
10 An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder Completed NCT02258828 Phase 4 Memantine;Placebo
11 Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder Completed NCT00120250 Phase 4 Eszopiclone
12 Naltrexone and Cognitive-Behavioral Therapy for Patients With Alcoholism and Post-Traumatic Stress Disorder Completed NCT00006489 Phase 4 Naltrexone;Placebo
13 Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy Completed NCT01087736 Phase 4 Topiramate
14 Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD) Completed NCT00203463 Phase 4 topiramate
15 Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder Among Veterans of Operation Enduring Freedom and Iraqi Freedom (OEF/OIF) Completed NCT01271244 Phase 4 Escitalopram
16 Combined Mirtazapine and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment of Post-traumatic Stress Disorder (PTSD) Completed NCT01178671 Phase 4 Mirtazapine;Sertraline
17 Randomized Trial of Sertraline, Prolonged Exposure, and Their Combination for Post-traumatic Stress Disorder (PTSD) in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF). Completed NCT01524133 Phase 4 Sertraline
18 Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study Completed NCT02287038 Phase 4 Atomoxetine 80 MG
19 Pilot Feasibility Study of Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder Completed NCT04188392 Phase 4 Pimavanserin
20 Treatment of Sleep Disturbances in Trauma-affected Refugees: A Randomised Controlled Trial Completed NCT02761161 Phase 4 Mianserin
21 Neurofunctional Markers of SSRI Treatment Response in PTSD Completed NCT00700999 Phase 4 Paroxetine
22 Evaluation of the Efficacy of Vortioxetine for Posttraumatic Stress Disorder Completed NCT02637895 Phase 4 Placebo;Vortioxetine
23 Retrospective Review of Ketamine Assisted Psychotherapy Program on Mental Health at Field Trip Health Centres in North America Completed NCT05604794 Phase 4
24 Combined Treatment With a Benzodiazepine (Clonazepam) and a Selective Serotonin Reuptake Inhibitor (Paroxetine) for Rapid Treatment of Posttraumatic Stress Disorder (PTSD) Completed NCT00025740 Phase 4 clonazepam and paroxetine
25 Prophylaxis of Posttraumatic Stress Disorder With Post-Trauma Propranolol Completed NCT00158262 Phase 4 Propranolol;Placebo
26 A Placebo-controlled, Randomized, Double-blind Comparison of Placebo vs Short Course Low Dose Corticosteroids on Posttraumatic Stress Disorder (PTSD) Completed NCT00204737 Phase 4 prednisone;placebo
27 Geodon (Ziprasidone) for Posttraumatic Stress Disorder Completed NCT00208208 Phase 4 Ziprasidone
28 12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
29 Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes Completed NCT00347269 Phase 4 Psychotropic medication optimization
30 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Posttraumatic Stress Disorder in Civilians Completed NCT00208130 Phase 4 Topiramate
31 Risperidone Monotherapy in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma: a Double-Blind, Placebo Controlled, Randomized Clinical Trial Completed NCT00208182 Phase 4 Risperidone
32 The Outcome of Treatment of Traumatised Refugees With Trauma-Focused Cognitive Behavioural Therapy and / or Antidepressants - a Randomised Controlled Trial Completed NCT00917397 Phase 4 Sertraline
33 Developing Memory Reconsolidation Blockers as Novel PTSD Treatments Completed NCT01490697 Phase 4 Mifepristone;d-Cycloserine;Placebo-matching Mifepristone;Placebo-matching d-Cycloserine (DCS)
34 The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy - a Randomised Clinical Study Completed NCT01569685 Phase 4 Venlafaxine;Sertraline
35 The Effect of Intranasal Oxytocin on Emphatic Abilities in Patients With PTSD Completed NCT01325168 Phase 4 syntocinon nasal spray;placebo nasal spray
36 Reducing Suicidal Ideation Through Treatment of Nightmares-PTSD Completed NCT02199652 Phase 4 Prazosin;Placebo
37 A Double-Blind, Placebo-Controlled, Flexible-Dose Pilot Clinical Trial of Once-Daily Extended-Release Tramadol for the Treatment of PTSD Completed NCT01517711 Phase 4 Tramadol;Placebo
38 Preventing Post-Operative Delirium in Pneumonectomy, Esophagectomy and Thoracotomy Patients Completed NCT02213900 Phase 4 Haloperidol;Placebo
39 A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD Completed NCT01959022 Phase 4 Doxazosin XL
40 Medication and Psychotherapy Treatment Trial for Psychogenic Nonepileptic Seizures Completed NCT00835627 Phase 4 sertraline
41 Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD) Completed NCT00560612 Phase 4 Paroxetine;Placebo
42 Treatment for Psychogenic Nonepileptic Seizures: A Pilot, 12 Week, Prospective, Randomized, Placebo-controlled, Double-blind, Clinical Trial of Sertraline in the Treatment of Comorbid Psychiatric Disorders in NES Completed NCT00159965 Phase 4 sertraline;placebo
43 A Placebo-controlled Trial of Adjunctive Quetiapine for Refractory PTSD Completed NCT00292370 Phase 4 Open Label (OL) Paroxetine;Placebo;Quetiapine
44 Effects of Hydrocortisone and D-Cycloserine on Fear Extinction in Veterans With Posttraumatic Stress Disorder Completed NCT00674570 Phase 4 Hydrocortisone;D-Cycloserine;Placebo
45 Minocycline for Treatment of Posttraumatic Stress Disorder in Veterans Completed NCT03340350 Phase 4 Minocycline
46 Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder Completed NCT01681849 Phase 4 Placebo;Paroxetine
47 Effects of Paxil CR on Neural Circuits in PTSD Completed NCT00672776 Phase 4 paroxetine;placebo
48 Influence of Hydrocortisone on Humoral and Cellular Immunologic Markers in High Risk Patients After Cardiac Surgery Completed NCT00490828 Phase 4 Hydrocortisone
49 Telemedicine Outreach for Post Traumatic Stress in CBOCs Completed NCT00821678 Phase 4
50 Effects of THC on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study Completed NCT03008005 Phase 4 Placebo Oral Capsule;Dronabinol Cap 5 milligrams (MG);Dronabinol Cap 10 milligrams (MG)

Search NIH Clinical Center for Post-Traumatic Stress Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carbamazepine
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
nefazodone
Paroxetine
Paroxetine Hydrochloride
Sertraline
Sertraline Hydrochloride
Tranylcypromine
Tranylcypromine sulfate

Cochrane evidence based reviews: stress disorders, post-traumatic

Genetic Tests for Post-Traumatic Stress Disorder

Genetic tests related to Post-Traumatic Stress Disorder:

# Genetic test Affiliating Genes
1 Post-Traumatic Stress Disorder 28

Anatomical Context for Post-Traumatic Stress Disorder

Organs/tissues related to Post-Traumatic Stress Disorder:

MalaCards : Brain, Prefrontal Cortex, Amygdala, Heart, Eye, Cortex, Spinal Cord

Publications for Post-Traumatic Stress Disorder

Articles related to Post-Traumatic Stress Disorder:

(show top 50) (show all 41194)
# Title Authors PMID Year
1
Impact of different cover letter information and incentives on Veterans' emotional responses to an unsolicited mailed survey about military traumas: a randomized, 3x2x2 factorial trial. 62 41
36456912 2022
2
Cognitive Processing Therapy or Relapse Prevention for comorbid Posttraumatic Stress Disorder and Alcohol Use Disorder: A randomized clinical trial. 62 41
36445895 2022
3
Antepartum and labour-related single predictors of non-participation, dropout and lost to follow up in a randomised controlled trial comparing internet-based cognitive-behaviour therapy with treatment as usual for women with negative birth experiences and/or post-traumatic stress following childbirth. 41
36442895 2022
4
Association study of trauma load and SLC6A4 promoter polymorphism in posttraumatic stress disorder: evidence from survivors of the Rwandan genocide. 53 62
20441718 2010
5
A prospective study of serotonin transporter gene promoter (5-HTT gene linked polymorphic region) and intron 2 (variable number of tandem repeats) polymorphisms as predictors of trauma response to mild physical injury. 53 62
19895335 2010
6
The D2 dopamine receptor gene variant C957T affects human fear conditioning and aversive priming. 53 62
19900188 2010
7
Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder. 53 62
19576571 2009
8
Candidate-gene approach in fibromyalgia syndrome: association analysis of the genes encoding substance P receptor, dopamine transporter and alpha1-antitrypsin. 53 62
20074437 2009
9
Serotonin transporter gene (SLC6A4) promoter polymorphisms and the susceptibility to posttraumatic stress disorder in the general population. 53 62
19487392 2009
10
Modification of the association between serotonin transporter genotype and risk of posttraumatic stress disorder in adults by county-level social environment. 53 62
19228812 2009
11
The DRD2 gene 957C>T polymorphism is associated with posttraumatic stress disorder in war veterans. 53 62
18833581 2009
12
Adrenocortical responsiveness to infusions of physiological doses of ACTH is not altered in posttraumatic stress disorder. 53 62
19893760 2009
13
Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. 53 62
19897083 2009
14
Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder. 53 62
18213623 2008
15
Blunted ACTH response to dexamethasone suppression-CRH stimulation in posttraumatic stress disorder. 53 62
18342888 2008
16
Effects of trauma-related audiovisual stimulation on cerebrospinal fluid norepinephrine and corticotropin-releasing hormone concentrations in post-traumatic stress disorder. 53 62
18295412 2008
17
Mice that under- or overexpress glucocorticoid receptors as models for depression or posttraumatic stress disorder. 53 62
18037007 2008
18
Elevated plasma corticotrophin-releasing hormone levels in veterans with posttraumatic stress disorder. 53 62
18037027 2008
19
The serotonin transporter genotype and social support and moderation of posttraumatic stress disorder and depression in hurricane-exposed adults. 53 62
17974934 2007
20
Monoamine oxidase (MAO) intron 13 polymorphism and platelet MAO-B activity in combat-related posttraumatic stress disorder. 53 62
17289152 2007
21
Glucocorticoid receptor activation is involved in producing abnormal phenotypes of single-prolonged stress rats: a putative post-traumatic stress disorder model. 53 62
17644267 2007
22
[Psychoneuroendocrinology of posttraumatic stress disorder]. 53 62
17546347 2007
23
Mineralocorticoid receptor function in posttraumatic stress disorder after pretreatment with metyrapone. 53 62
16566900 2006
24
No association between the Clara cell secretory protein (CC16) gene polymorphism and personality traits. 53 62
16764982 2006
25
The D2 dopamine receptor (DRD2) gene is associated with co-morbid depression, anxiety and social dysfunction in untreated veterans with post-traumatic stress disorder. 53 62
16632165 2006
26
Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. 53 62
16325152 2006
27
NPY and extreme stress: lessons learned from posttraumatic stress disorder. 53 62
16383009 2006
28
Expression of c-fos and BDNF mRNA in subregions of the prefrontal cortex of male and female rats after acute uncontrollable stress. 53 62
15993862 2005
29
Glucocorticoid receptor polymorphisms and post-traumatic stress disorder. 53 62
15511603 2005
30
No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorder. 53 62
15677606 2005
31
Neurobiological characteristics of rhesus macaque abusive mothers and their relation to social and maternal behavior. 53 62
15652254 2005
32
Increased adrenocorticotropin suppression after dexamethasone administration in sexually abused adolescents with posttraumatic stress disorder. 53 62
15677426 2004
33
Increased adrenocorticotropin suppression following dexamethasone administration in sexually abused adolescents with posttraumatic stress disorder. 53 62
15288707 2004
34
An increased capacity for adrenal DHEA release is associated with decreased avoidance and negative mood symptoms in women with PTSD. 53 62
15199367 2004
35
The ACTH response to dexamethasone in PTSD. 53 62
15285965 2004
36
Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. 53 62
15269266 2004
37
Pituitary volumes in pediatric maltreatment-related posttraumatic stress disorder. 53 62
15039005 2004
38
Effect of topiramate on glucocorticoid receptor mediated action. 53 62
14666121 2004
39
Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. 53 62
14675802 2003
40
Stress responsive neurohormones in depression and anxiety. 53 62
14677081 2003
41
D2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorder. 53 62
12957328 2003
42
The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems. 53 62
12606697 2003
43
Cerebrospinal fluid corticotropin-releasing factor (CRF) and vasopressin concentrations predict pituitary response in the CRF stimulation test: a multiple regression analysis. 53 62
12629539 2003
44
Flow cytometric determination of glucocorticoid receptor (GCR) expression in lymphocyte subpopulations: lower quantity of GCR in patients with post-traumatic stress disorder (PTSD). 53 62
12562397 2003
45
D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. 53 62
12497624 2003
46
Endocrine and cardiovascular responses to corticotropin-releasing hormone in patients with posttraumatic stress disorder: a role for atrial natriuretic peptide? 53 62
12707494 2003
47
Mineralocorticoid receptor function in patients with posttraumatic stress disorder. 53 62
12411234 2002
48
The cortisol and glucocorticoid receptor response to low dose dexamethasone administration in aging combat veterans and holocaust survivors with and without posttraumatic stress disorder. 53 62
12242055 2002
49
Harmful drinking in military veterans with post-traumatic stress disorder: association with the D2 dopamine receptor A1 allele. 53 62
12217937 2002
50
Increased pituitary and adrenal reactivity in premenopausal women with posttraumatic stress disorder. 53 62
11750893 2001

Variations for Post-Traumatic Stress Disorder

Expression for Post-Traumatic Stress Disorder

Search GEO for disease gene expression data for Post-Traumatic Stress Disorder.

Pathways for Post-Traumatic Stress Disorder

Pathways related to Post-Traumatic Stress Disorder according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1 13.51 BDNF CNR1 CRH CRHR1 DRD2 FOS
2
Show member pathways
13.42 POMC NPY HTR2A HTR1A DRD2 CRHR1
3
Show member pathways
13.22 POMC NPY HTR2A HTR1A DRD2 CRHR1
4
Show member pathways
12.47 POMC FOS CRHR1 CRH CNR1 BDNF
5 11.83 SLC6A4 NR3C1 MAOA HTR2A HTR1A BDNF
6
Show member pathways
11.8 HTR2A HTR1A DRD2
7 11.79 POMC MAOA FOS
8 11.72 POMC FOS CRHR1 CRH
9
Show member pathways
11.66 NR3C1 FOS BDNF
10 11.62 POMC NR3C1 FOS
11
Show member pathways
11.51 BCL2A1 FOS NR3C1
12
Show member pathways
11.49 NR3C1 HTR2A FOS
13
Show member pathways
11.32 SLC6A4 SLC6A3 MAOA
14
Show member pathways
11.05 SLC6A4 SLC6A3 MAOA
15 11 SLC6A4 MAOA HTR2A HTR1A
16 10.91 DRD2 NPY POMC
17
Show member pathways
10.72 SLC6A4 SLC6A3 MAOA HTR1A DRD2
18
Show member pathways
10.56 POMC HTR2A HTR1A FOS CRHR1 CRH
19 10.39 POMC CRHR1 CRH

GO Terms for Post-Traumatic Stress Disorder

Cellular components related to Post-Traumatic Stress Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.34 SLC6A4 SLC6A3 HTR2A HTR1A DRD2 CRHR1
2 plasma membrane GO:0005887 10.34 SLC6A4 SLC6A3 HTR2A HTR1A DRD2 CRHR1
3 synapse GO:0045202 9.96 CNR1 CRH DRD2 HTR1A HTR2A NR3C1
4 presynaptic membrane GO:0042734 9.7 SLC6A4 SLC6A3 HTR2A DRD2 CNR1
5 obsolete integral component of postsynaptic membrane GO:0099055 9.26 SLC6A4 SLC6A3 HTR2A DRD2
6 obsolete integral component of presynaptic membrane GO:0099056 9.02 SLC6A4 SLC6A3 HTR2A DRD2 CNR1

Biological processes related to Post-Traumatic Stress Disorder according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 response to xenobiotic stimulus GO:0009410 10.18 SLC6A4 SLC6A3 HTR2A FOS DRD2
2 signal transduction GO:0007165 10.06 BDNF CNR1 CRH CRHR1 DRD2 HTR1A
3 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 10 DRD2 CRHR1 CNR1
4 response to ethanol GO:0045471 10 CNR1 DRD2 FOS SLC6A3
5 response to nicotine GO:0035094 9.97 SLC6A3 DRD2 CNR1
6 memory GO:0007613 9.92 SLC6A4 HTR2A CNR1 BDNF
7 behavioral response to ethanol GO:0048149 9.91 DRD2 CRHR1
8 response to cocaine GO:0042220 9.91 SLC6A3 DRD2 CNR1
9 dopamine catabolic process GO:0042420 9.89 SLC6A3 MAOA
10 monoamine transport GO:0015844 9.88 SLC6A4 SLC6A3
11 adenohypophysis development GO:0021984 9.88 SLC6A3 DRD2
12 negative regulation of blood pressure GO:0045776 9.88 NPY DRD2 CNR1
13 serotonin receptor signaling pathway GO:0007210 9.87 HTR1A HTR2A
14 hyaloid vascular plexus regression GO:1990384 9.85 DRD2 SLC6A3
15 adrenal gland development GO:0030325 9.85 CRH CRHR1 NR3C1
16 dopamine uptake involved in synaptic transmission GO:0051583 9.84 SLC6A3 DRD2
17 negative regulation of dopamine secretion GO:0033602 9.81 DRD2 CNR1
18 regulation of synaptic vesicle exocytosis GO:2000300 9.7 NPY HTR2A DRD2
19 aging GO:0007568 9.65 SLC6A3 NPY HTR2A FOS CNR1
20 behavior GO:0007610 9.56 HTR1A HTR2A
21 regulation of corticosterone secretion GO:2000852 9.56 POMC CRHR1
22 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.23 NPY HTR2A HTR1A CNR1

Molecular functions related to Post-Traumatic Stress Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.65 SLC6A3 POMC NPY DRD2 CRH BDNF
2 monoamine transmembrane transporter activity GO:0008504 9.56 SLC6A4 SLC6A3
3 dopamine binding GO:0035240 9.46 SLC6A3 DRD2
4 serotonin binding GO:0051378 9.1 SLC6A4 HTR2A HTR1A

Sources for Post-Traumatic Stress Disorder

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....